Company Overview and News

 
Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of July 16

2018-07-15 seekingalpha
It has been the typical mid-summer lull and dividend increases have slowed significantly. There are two Canadian Dividend All-Stars scheduled to report earnings this week, Exchange Income Fund (OTCPK:EIFZF)[TSX:EIF] and Atrium Mortgage Investment Corp. (OTC:AMIVF)[TSX:AI]. Neither are expected to raise dividends as both have already announced a dividend bump earlier this year. That being said, earnings are scheduled to ramp up, so let’s revisit some of the action from the past number of weeks.
ANCUF ATD.A ANCTF ATD.B AI EIF AMIVF EIFZF EMLAF

 
Atrium Mortgage Investment Corporation Announces Increase to Bought Deal Financing

2018-07-10 globenewswire
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
AI AMIVF

 
Atrium Mortgage Investment Corporation Announces $25 Million Public Offering of Convertible Unsecured Subordinated Debentures

2018-07-09 globenewswire
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
AI AMIVF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:AI / Atrium Mortgage Investme on message board site Silicon Investor.

Mainstream Politics and Economics Mainstream Politics and Economics Mainstream Politics and Economics Human Brain, The Human Brain, The Human Brain, The
Blockchain and Cryptocurrencies Blockchain and Cryptocurrencies Blockchain and Cryptocurrencies American Airlines Group, Inc. American Airlines Group, Inc. American Airlines Group, Inc.
Waiting for the big Kahuna Waiting for the big Kahuna Waiting for the big Kahuna wagerr - betting belongs on the blockchain wagerr - betting belongs on the blockchain wagerr - betting belongs on the blockchain
Copper Mountain Mining Corporation (CUM.TO) -Toronto Copper Mountain Mining Corporation (CUM.TO) -Toronto Copper Mountain Mining Corporation (CUM.TO) -Toronto American Presidential Politics and foreign affairs American Presidential Politics and foreign affairs American Presidential Politics and foreign affairs
Foreign Affairs Discussion Group Foreign Affairs Discussion Group Foreign Affairs Discussion Group 50% Gains Investing 50% Gains Investing 50% Gains Investing